Aarti Pharmalabs will host an earnings conference call on Monday, August 10, 2026, at 4:00 PM IST to discuss its Q1FY27 financial results. The event provides investors and analysts with a direct channel to review the company’s performance for the quarter ended June 30, 2026, and seek clarification on operational metrics. This disclosure ensures timely access to material information regarding the firm’s recent financial standing.

The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Aarti Pharmalabs submitted the intimation to the Listing/Compliance Departments of both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). Jeevan Bhargav Mondkar, Company Secretary and Legal Head, signed the communication on behalf of the board.

Management Participation

The management team representing Aarti Pharmalabs during the conference call includes senior leadership responsible for strategic and financial oversight. Investors can expect insights from the following executives:

Conference Call Details

The earnings call is being facilitated by 360 ONE Capital Market Research. Participants can join via the provided Diamond Pass link or through universal dial-in numbers available for domestic and international attendees. For further assistance, investors may contact Rohit Bhat or Maulik Varia at 360 ONE Capital Market Research.

What the Numbers Show

While specific financial figures for Q1FY27 are not detailed in this scheduling notice, the convening of the call signals the completion of the quarter’s reporting cycle. The participation of both the Chairman and the CFO suggests that the discussion will likely cover both strategic direction and detailed financial performance, offering a comprehensive view of the company’s position in the pharmaceutical sector for the period.

Aarti Pharmalabs Limited inaugurated a new state-of-the-art manufacturing block at Tarapur Unit 5, Maharashtra, on June 30, 2026, to expand its production capabilities. The facility adds 3600 TPA capacity for Xanthine derivatives manufacturing, increasing the company's total capacity to 9600 TPA. This expansion positions Aarti Pharmalabs among the top three global manufacturers of Xanthine derivatives.

The company has successfully obtained all necessary permissions and approvals to commence operations at the new site. Trial production has already been initiated, and management plans to ramp up the facility for optimum utilization over the next few quarters.

Rashesh Gogri, Chairman of Aarti Pharmalabs, highlighted the significance of this development, stating that it represents a major leap forward for the company. He emphasized that the expanded capabilities will strengthen the company's ability to serve its business partners effectively.

Capacity Expansion Details

The new block is located at Tarapur, MIDC, Plot No. L-28/29/99. The following table outlines the capacity changes:

The inauguration event was attended by the senior management team and dedicated members of the Aarti Pharmalabs team. The new facility underscores the company's commitment to growth and capability development to meet the needs of large customers.

About Aarti Pharmalabs Limited

Aarti Pharmalabs Limited is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence. The company specializes in offering comprehensive CDMO/CMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies. Its dedicated facilities handle HPAPIs, corticosteroids, cytotoxic, and oncology products. Additionally, it offers generic APIs and intermediates.